Today’s guest is Patricio La Rosa, Head of End-to-End Decision Science in Seed Production Innovation at Bayer Crop Science. Patricio joins the AI in Business podcast to explore how AI is transforming the clinical trial lifecycle, from biomarker discovery to long-term patient engagement. Drawing on his academic expertise, Patricio explains how AI-powered systems such as metagenomics, NLP, and multimodal sensing are helping researchers identify robust biomarkers and predict patient outcomes more effectively. He emphasizes the importance of reproducibility, effect traceability, and the scalability of sensing modalities from trial design to clinical practice. Patricio’s discussion with Emerj Editorial Director Matthew DeMello then shifts to the human element — how to build trust with patients, improve adherence, and balance transparency with innovation. With deep insight and clarity, Patricio challenges industry leaders to rethink clinical trials not just as scientific protocols—but as collaborative, data-driven partnerships with future customers. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business’ podcast! If you’ve enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
